We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.
- Authors
Baik, Christina S.; Myall, Nathaniel J.; Wakelee, Heather A.
- Abstract
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths globally. However, the identification of oncogenic driver alterations involved in the initiation and maintenance of NSCLC, such as epidermal growth factor receptor muta-tions and anaplastic lymphoma kinase translocation, has led to the development of novel therapies that directly target mutant proteins and associated signaling pathways, resulting in improved clinical outcomes. As sequencing techniques have improved, the molecular heterogeneity of NSCLC has become apparent, leading to the identification of a number of potentially actionable oncogenic driver mutations. Of these, one of the most promising therapeutic targets is B-Raf proto-oncogene, serine/threonine kinase (BRAF). Mutations in BRAF, observed in 2%-4% of NSCLCs, typically lead to constitutive activation of the protein and, as a consequence, lead to activation of the mitogen-activated protein kinase signaling pathway. Direct inhibition of mutant BRAF and/ or the downstream mitogen-activated protein kinase kinase (MEK) has led to prolonged survival in patients with BRAF- mutant metastatic melanoma. This comprehensive review will discuss the clinical characteristics and prognostic implications of BRAF-mutant NSCLC, the clinical development of BRAF and MEK inhibitors from melanoma to NSCLC, and practical considerations for clinicians involving BRAF mutation screening and the choice of targeted therapy.
- Subjects
LUNG cancer prognosis; PROTEIN kinase inhibitors; CELLULAR signal transduction; LUNG cancer; GENETIC mutation; ONCOGENES; GENETIC testing; INDIVIDUALIZED medicine; GENE expression profiling; THERAPEUTICS
- Publication
Oncologist, 2017, Vol 22, Issue 7, p786
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2016-0458